The Productivity Bureau has appointed Zhengmei Pharmaceuticals as the technical advisor for the "New Industrial Acceleration Program" project

The Hong Kong Productivity Council has officially appointed Jacobson Pharma (02633.HK) subsidiary, Zhengmei Pharmaceuticals, as the technical consultant for its "New Industrial Acceleration Program," providing comprehensive smart manufacturing technology assessments and recommendations for Zhengmei Pharmaceuticals' new factory development.

In this collaboration, the Productivity Council will offer customized assessment recommendations for factory and production line layout, intelligent system design, and specification requirements, as well as assist in system delivery, debugging, and validation. Leveraging its expertise in artificial intelligence and robotics technology, the Productivity Council will work with Zhengmei Pharmaceuticals to tailor seven intelligent production lines for oral solid dosage packaging, enhancing the company's production efficiency and quality control through advanced AI and robotics technology. The Productivity Council will also provide advice on the development of mobile robotic solutions to assist Zhengmei Pharmaceuticals in achieving automation in warehousing and material distribution, supporting its transformation and upgrading.

This project is set to commence within this year, with the production line expected to begin trial production and operation by the end of 2028. The total budget for this project is approximately HKD 600 million, with an expected funding amount of around HKD 200 million from the "Acceleration Program."

The Chairman of the Hong Kong Productivity Council, Chan Chu-hang, stated that as a market-oriented international new R&D institution, the Productivity Council has been actively cooperating with the Hong Kong SAR government to develop strategic life and health technology industries through the "Acceleration Program," establishing smart production lines in Hong Kong to drive the collaborative development of the upstream and downstream industrial chain with products of "Hong Kong R&D" and "Hong Kong Manufacturing," promoting the new industrialization of Hong Kong.

The Chairman and CEO of Jacobson Pharma, Chan Kwong-yeung, indicated that the Zhengmei Pharmaceuticals factory in Tai Po Innovation Park has become the first project supported by the "New Industrial Review Committee" under the "Acceleration Program," marking an important step in the company's corporate development and a key milestone in Hong Kong's medical innovation field. He believes this project will set a demonstration case for the intelligent development of Hong Kong's life and health technology industry, further consolidating Hong Kong's competitiveness in the innovation and technology sector